Manifestation eines Diabetes mellitus unter Therapie mit Olanzapin

Zusammenfassung

Eine potenzielle Nebenwirkung der Olanzapintherapie ist die Manifestation eines Diabetes mellitus. Mögliche pathogenetische Mechanismen werden diskutiert, wobei der Minderung der Insulinempfindlichkeit infolge einer Gewichtszunahme entsprechend der Datenlage die größte Relevanz zukommt.

Abstract

A potential side-effect in the treatment with olanzapine is hyperglycemia or new onset diabetes mellitus. There are possible mechanisms by which olanzapine could interfere with glucose metabolism but decreased insulin sensitivity due to weight gain is of most relevance.

Literatur

• 1 Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis.  Austr New Zealand J Psych. 1999;  33 120-121
• 2 Colli A, Cocciolo M, Francobandiera G, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment.  Diabetes Care. 1999;  22 176-177
• 3 Pierides M. Clozapine monotherapy and ketoacidosis.  Br J Psychiatry. 1997;  171 90-91
• 4 Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment.  Diabetes Care. 1999;  22 1002-1003
• 5 Hauptmann B, Kupsch A, Arnold G. Hyperglycemia associated with low-dose clozapine treatment.  J Neural Transm. 1999;  106 XII
• 6 Fertig M K, Brooks V G, Shelton P S, English C W. Hyperglycemia associated with olanzapine.  J Clin Psychiatry. 1998;  59 687-689
• 7 Hayek D, Hüttl V, Reiss J, Schweiger H D, Füeßl H S. Hyperglykämie und Ketoazidose unter Olanzapin.  Nervenarzt. 1999;  70 836-837
• 8 Lindenmayer J P, Patel R. Olanzapine-induced ketoacidosis with diabetes mellitus.  Am J Psychiatry. 1999;  156 1471
• 9 Goldstein L E, Sporn J, Brown S, Kim H, Finkelstein J, Gaffey G K, Sachs G, Stern T A. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.  Psychosomatics. 1999;  40 438-443
• 10 Selva K A, Scott S M. Diabetic ketoacidosis associated with olanzapine in an adolescent patient.  J Pediatr. 2001;  138 936-938
• 11 Wirshing D A, Spellberg B J, Erhart S M, Marder S R, Wirshing W C. Novel antipsychotics and new onset diabetes.  Biol Psychiatry. 1998;  44 778-783
• 12 Ober S K, Hudak R, Rusterholz A. Hyperglycemia and olanzapine.  Am J Psychiatry. 1999;  156 970
• 13 Roefaro J, Mukherjee S M. Olanzapine-induced hyperglycemic nonketotic coma.  Ann Pharmacother. 2001;  35 300-302
• 14 Naber D, Lambert M, Krausz M, Haasen C. Atypische Neuroleptika in der Behandlung schizophrener Patienten. Bremen; UNI-MED 2000
• 15 Howarth P, Emanuel M, Holgate S. Astemizole, a potent histamine H1 receptor antagonist: effect on allergic rhinoconjunctivitis, on antigen and histamine induced skin response and relationship to serum levels.  Br J Clin Pharmacol. 1984;  18 1-8
• 16 Wilson J D, Hillas S L. Astemizole: a new long-acting antihistamine in the treatment of seasonal allergic rhinitis.  Clin Allergy. 1983;  13 131-140
• 17 Melkersson K, Hulting A L, Brismar K E. Elevated levels of insulin, leptin, and lipids in olanzapine-treated patients with schizophrenia or related psychosis.  J Clin Psychiatry. 2000;  61 742-749
• 18 Seaburg H L, McLendon B M, Doraiswamy P M. Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.  Pharmacotherapy. 2001;  21 1448-1454
• 19 Lindenmayer J P, Nathan A M, Smith R C. Hyperglycemia associated with the use of atypical antipsychotics.  J Clin Psychiatry. 2001;  62 30-38
• 20 Knauf H. Nebenwirkungen der Diuretika.  Nieren- und Hochdruckkrankheiten. 1996;  4 184-191
• 21 Langford H G, Cutter G, Oberman A, Kansal P, Russell G. The effect ot thiazide therapy and cholesterol metabolism and of glucose on potassium: results of a cross-sectional study in patients from the Hypertension Detection and Follow-up Program.  J Hum Hypertension. 1990;  4 491-500